Nplex Biosciences develops proteomics tools using nanotechnology, including the nELISA platform for high-throughput protein measurement. The platform uses DNA nanotechnology to identify proteins on micron-sized beads, enabling miniaturized, highly parallel immunoassays. It differentiates itself by combining DNA-based protein identification with bead-based assays and a scalable, cost-efficient workflow that lowers the cost of antibody-based proteomics. Its goal is to provide a reliable, scalable proteomics platform that supports drug discovery, biomarker discovery, and personalized medicine.
Company Size
51-200
Company Stage
Series B
Total Funding
$60.1M
Headquarters
Montreal, Canada
Founded
2017
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?